{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:48:02Z","timestamp":1761648482732,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:00:00Z","timestamp":1558137600000},"content-version":"vor","delay-in-days":137,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.5604\/01.3001.0012.7931","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T06:14:14Z","timestamp":1544768054000},"page":"236-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done"],"prefix":"10.1016","volume":"18","author":[{"given":"Susana","family":"Llerena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Cabezas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Manuel Olmos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.5604\/01.3001.0012.7931_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2016.","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0012.7931_bib0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short-duration treatment with elbasvir\/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"10.5604\/01.3001.0012.7931_bib0020","series-title":"American Association for the Study of Liver Diseases (AASLD)","article-title":"Retreatment with Sofosbuvir + Grazo-previr + Elbasvir + Ribavirin of Patients with Hepatitis C Virus Genotype 1 or 4 with RASs at Failure of a Sofosbuvir + Ledipasvir or + Declatasvir or + Simeprevir Regimen","author":"De Ledinghen","year":"2016"},{"key":"10.5604\/01.3001.0012.7931_bib0025","series-title":"The Liver Meeting Boston","article-title":"Elbasvir\/Grazoprevir plus Sofosbuvir \u00b1 Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: The C-ISLE Study. Vol. 64","author":"Foster","year":"2016"},{"key":"10.5604\/01.3001.0012.7931_bib0030","series-title":"67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)","first-page":"102A","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor experienced patients with genotype 1-6 infection: The phase 3 POLARIS-1 study [Abstract 194]. Vol 64.","author":"Bourliere","year":"2016"},{"key":"10.5604\/01.3001.0012.7931_bib0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","article-title":"High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"10.5604\/01.3001.0012.7931_bib0040","series-title":"American Association for the Study of Liver Disease (AASLD)","first-page":"61A","article-title":"High SVR rates in patients with chronic HCV GT1, 2 or 3 infection following 16 weeks of MK-3682\/ grazoprevir\/MK-8408 plus ribavirin after failure of 8 weeks of therapy (Part C of C-CREST-1 & 2) Vol 64. Abstract 112.","author":"Serfaty","year":"2016"},{"key":"10.5604\/01.3001.0012.7931_bib0045","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1038\/s41598-017-02968-7","article-title":"Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.","volume":"7","author":"Palladino","year":"2017","journal-title":"Sci Rep"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:42:18Z","timestamp":1761648138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119303291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1665268119303291"],"URL":"https:\/\/doi.org\/10.5604\/01.3001.0012.7931","relation":{},"ISSN":["1665-2681"],"issn-type":[{"type":"print","value":"1665-2681"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/01.3001.0012.7931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}